N6-methyladenosine demethylase FTO promotes growth and metastasis of gastric cancer via m6A modification of caveolin-1 and metabolic regulation of mitochondrial dynamics

You Zhou1,2,3, Qi Wang1,2,3, Haifeng Deng1,2,3, Bin Xu1,2,3, Yi Zhou1,2,3, Jian Liu1,2,3, Yingting Liu1,2,3, Yufang Shi4, Xiao Zheng1,2,3, and Jingting Jiang1,2,3,4

Gastric cancer (GC) is the fifth most common tumor and the third most deadly cancer worldwide. N6-methyladenosine (m6A) modification has been reported to play a regulatory role in human cancers. However, the exact role of m6A in GC remains largely unknown, and the dysregulation of m6A on mitochondrial metabolism has never been studied. In the present study, we demonstrated that FTO, a key demethylase for RNA m6A modification, was up-regulated in GC tissues, especially in tissues with liver metastasis. Functionally, FTO acted as a promoter for the proliferation and metastasis in GC. Moreover, FTO enhanced the degradation of caveolin-1 mRNA via its demethylation, which regulated the mitochondrial fission/fusion and metabolism. Collectively, our current findings provided some valuable insights into FTO-mediated m6A demethylation modification and could be used as a new strategy for more careful surveillance and aggressive therapeutic intervention.

Cell Death and Disease (2022) 13:72; https://doi.org/10.1038/s41419-022-04503-7

INTRODUCTION
Gastric cancer (GC) is the fifth most common tumor and the third most deadly cancer worldwide, with almost half of global GC cases diagnosed in East Asia [1]. Most GC patients are first diagnosed in the late stage of malignant hyperplasia and metastasis [2]. Unfortunately, the prognosis for patients with advanced GC remains poor [3]. Therefore, it is urgently necessary to identify new biomarkers and therapeutic targets for the diagnosis and treatment of GC.

Dysfunction of energy metabolism is thought to be a distinct feature of cancer [4]. Cancer cells support the occurrence and development of malignant tumors through metabolic recombination, especially mitochondrial metabolism [5]. Glycolysis has long been considered as the main metabolic process for energy production and anabolic growth of cancer cells [6]. Although such insights are instrumental in the development of powerful imaging tools that are still used in clinics, it is now clear that mitochondria play a key role in tumorigenesis [7]. In addition to its central bioenergy role, mitochondria indeed provide a cornerstone for tumor anabolism, control of redox and calcium homeostasis, participation in transcriptional regulation, and regulation of cell death [8, 9]. Mitochondria are therefore promising targets for the development of new anticancer drugs [10, 11]. Moreover, it is critical to understand the molecular mechanisms of mitochondrial metabolism in GC in order to develop future diagnostic and therapeutic strategies.

As the most common internal chemical modification of RNA in eukaryotes, N6-methyladenosine (m6A) modification is a reversible process mediated by m6A methyltransferase methyltransferase-like 3 (METTL3), methyltransferase-like 14 (METTL14), tumor 1 associated protein (WTAP), and elimination of fat mass and obesity-associated protein (FTO) or alkylation repair homologous protein 5 (ALKBH5) [12, 13]. In mammals, such modification affects different aspects of RNA metabolism, leading to mRNA stability and splicing, translation efficiency, nuclear output, selective polyadenylation, and microRNA processing [14]. Recent studies have revealed the effects of m6A modification on many biological processes, including fertility, immune regulation, metabolism, stem maintenance, and differentiation [12, 15]. Importantly, RNA m6A modification has been reported to play a regulatory role in human cancers [16–18]. For example, ALKBH5 maintains the tumorigenicity of glioblastoma stem cell-like cells [14]. FTO regulates chemoradiotherapy resistance of cervical squamous cell carcinoma [19, 20]. METTL3 controls myeloid differentiation in normal hematopoietic cells and leukemic cells [21]. A growing number of studies have confirmed the role of m6A in a variety of malignancies [13, 21]. However, the exact role of m6A in GC remains largely unknown, and the dysregulation of m6A on mitochondrial metabolism has never been studied.

In the present study, we demonstrated that FTO, a key demethylase for RNA m6A modification, played a key role in promoting proliferation and metastasis in GC. Collectively, our...
findings provided some valuable insights into FTO-mediated m6A demethylation modification. Moreover, we also explored the molecular mechanisms underlying the GC metastasis by identifying downstream target genes and signals.

MATERIALS AND METHODS

Cell lines and cell culture

All cells used in this study were obtained from the Chinese Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Human GC cell lines AGS and SGC-7901 were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin solution. Lentivirus was used to establish individual stable cell lines. Small interfering RNA (siRNA) duplexes targeting FTO (5’-GACGATGTATCTGGAGCTC-3’; 100 nM), caveolin-1 (5’-TGTGACGAGAATACCTGTTTAC-3’; 100 nM) and corresponding negative control (NC) oligonucleotides were transfected into cells using Lipofectamine 3000 (Invitrogen) according to the manufacturer’s instructions.

Cell proliferation assay

Cell proliferation assay was performed using CCK-8 kit (Dojindo) as previously reported. Briefly, cells were seeded into a 96-well plate (100 μl/well) at a density of 1 × 10^4 cells/ml and cultured at 37 °C in an incubator containing 5% CO2. Each well was added with 10 μl CCK-8 solution, followed by incubation at 37 °C for 2 h. The spectrophotometric absorbance at a wavelength of 450 nm was determined for each sample.

Western blotting analysis

The cells were directly lysed in 1× sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer and subjected to SDS-PAGE. The blots were sequentially incubated with primary and HRP-conjugated secondary antibodies. The immunoreactive bands were then visualized using a Chemiluminescence Detection Kit (Servicebio, Wuhan, China) and detected with an imaging system (Bio-Rad, USA). Antibodies against FTO (1:2000, RRID: AB_280081) and caveolin-1 (1:1500, RRID: AB_32577) were obtained from Abcam. Antibodies against Parkin1 (1:1500, Cat#6946), MFN2 (1:1000, Cat#11925), p-Parkin1 (1:1500, Cat#36728), Parkin1 (1:1000, Cat#2131), Cytochrome c (1:2000, Cat#12963) and β-tubulin (1:1500, Cat#2146) were obtained from Cell Signalling Technology. Antibody against p-MFN2 (1:3000, Cat#ABC963) was obtained from Merck Millipore. Antibody against GAPDH (1:5000, Cat# 60004) antibodies was purchased from Proteintek.

RNA-seq and data analysis

Total RNA from AGS cells with or without FTO depletion was subjected to HiSeq RNA-Seq. Transcriptome reads from RNA-Seq experiments were mapped to the reference genome (hg19) using the Bowtie tool. The gene expression level was quantified by the RSEM software package. p < 0.05 was considered statistically significant. The differentially expressed genes were subsequently analyzed for the enrichment of biological pathways using the ClusterProfiler package. Gene interaction network analysis was performed using STRING website (https://string-db.org/) and Cytoscape software (3.6.0).

Wound-healing assay

The cell migration ability was assessed by using a wound-healing assay to examine the regulatory role of FTO and caveolin-1 in AGS cells as previously described.

Transwell invasion assay

The transwell culture system was adopted to examine the invasive ability of FTO and caveolin-1 in GC cells as previously described.

Mitochondrial fission assay

Mitochondrial fission was analyzed by staining mitochondria with 100 nM MitoTracker Green (Molecular Probes, Eugene, OR, USA). Cells were fixed in 4% parafomaldehyde (PFA) for 15 min. and permeabilized with 0.2% Triton X-100. Mitochondria were imaged using a laser scanning confocal microscope (Zeiss LSM 800, Dublin, USA).

Tumor xenografts

Male BALB/c nude mice (5 weeks old) were purchased from SLAC Animal Center (Shanghai, China) and then used for the xenograft tumor model. The animal-related protocols were approved by the Institutional Animal Care and Use Committee of the Third Affiliated Hospital of Soochow University. For the tumor growth analysis, AGS cells were subcutaneously injected into nude mice, and then the tumor volumes were monitored every 5 days. Tumor volumes were estimated based on the length and width and calculated using the following formula: tumor volume = (length × width^2)/2. About 1 month later, the nude mice were sacrificed, and then tumors were excised, pictured, and weighed. For the tumor metastasis analysis, AGS cells were injected into nude mice by Tail Vein. About 1 month later, the nude mice were sacrificed, and then lung with metastasis lesions were excised, pictured, and counted.

Immunohistochemistry (IHC) assays

Tumor slides from xenograft models and tissue array kit were collected and then embedded by paraffin after fixed in 4% PFA. IHC analyses were performed using specific anti-FTO (1:300, RRID:AB_280081) and anti-caveolin-1 (1:300, RRID: AB_32577) antibodies.

Measurement of oxidative phosphorylation

Real-time integrated cellular oxygen consumption rate (OCR) was measured using the Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) as previously described. Briefly, AGS
The expression of FTO at the mRNA level and the prognostic value in GC, A The expression of FTO at the mRNA level and B the prognostic value in gastric cancer tissues were analyzed in the clinical database GEPIA (http://gepia.cancer-pku.cn/). C The expression of FTO at the protein level in the GC tissue microarray consisting of 90 cases was analyzed using IHC. D Quantitative analysis was performed upon the IHC data. *p < 0.05, **p < 0.01 compared with the indicated group.

RESULTS

FTO expression is up-regulated in GC tissues and its prognostic value in GC

To explore the expression profile of the major m6A eraser enzyme in GC, we first searched the clinical database GEPIA (http://gepia.cancer-pku.cn/) and found that the expression of FTO at the mRNA level in GC tissues was significantly higher compared with the normal tissues (Fig. 1A). Further analysis of survival data among metastatic individuals suggested that patients with high FTO expression had a shorter median survival time (Fig. 1B). We next examined the expression of FTO at the protein level in the GC tissue using a microarray consisting of 90 cases by IHC. Figure 1C shows that FTO was clearly located in the nucleus of GC cells. Besides, the positive expression of FTO was dominant in most GC liver metastasis tissues, which was further confirmed by quantitative analysis (Fig. 1D). Among them, 24 cases (26.67%) had weak staining, and 66 cases (73.33%) had strong staining. In addition, the expression of FTO was significantly increased with the increase of pN stage (p = 0.001), pT stage (p = 0.001), TNM stage (p < 0.001), and liver invasion (p = 0.008) (Table 1). Taken together, these data suggested that FTO was significantly involved in GC, especially in tumor liver metastasis, and it might be associated with metastatic progression of GC.

Down-regulated m6A and elevated level of FTO are shown in GC liver metastasis tissues

To confirm the observation of the elevated level of FTO in GC liver metastasis tissues, we then constructed a liver metastasis model of GC in male C57BL/6N mice, and the GC liver metastasis tissues were collected. Compared with the generated subcutaneous tumor in male C57BL/6 NOD mice, the level of m6A methylated RNA was dramatically decreased (Fig. 2A), which was further confirmed by m6A Dot blotting analysis (Fig. 2B). Consistently, the expression of FTO at the mRNA level was significantly increased in GC liver metastasis tissues (Fig. 2C). Moreover, we found the level of m6A was negatively relative with FTO mRNA expression in the tumor and liver metastasis tumor (Fig. 2D). Meanwhile, the expression of FTO at the protein level in GC tissues was analyzed by IF, and we found a similar increase in GC liver metastasis tissues (Fig. 2E). These results suggested that down-regulated m6A and elevated FTO were found in GC liver metastasis tissues.

Depletion of FTO impairs the proliferation and metastasis of GC cells in vitro and in vivo

To evaluate the biological function of FTO in GC cells, we then depleted FTO in AGS and SGC-7901 cells with specific siRNAs. Figure 3A shows that FTO depletion remarkably impaired the cellular viability (Fig. 3B), migration (Fig. 3C), and invasion (Fig. 3D) by CCK-8 assay, wound-healing assay, and transwell assay, respectively. To determine the role of FTO in GC cells in vivo, AGS cells infected with shFTO and NC lentiviruses were used to establish a subcutaneous tumor xenograft in Balb/c nude mice. We observed
the xenograft growth for 30 days and found that FTO depletion could significantly suppress the tumor growth in vivo (Fig. 3E). An orthotopic mouse model assay was also performed to further analyze the effect of FTO on metastasis. Luciferase-labeled AGS cells were injected beneath the serosa of the stomach of nude mice. Figure 3F shows that the number of metastatic nodes was dramatically decreased in FTO-depleted AGS cells. These results demonstrated that depletion of FTO impaired the proliferation and metastasis of GC cells in vitro and in vivo.

Transcriptome-sequencing finds that FTO directly targets caveolin-1 mRNA and promotes its degradation

To investigate the functional implications of FTO and identify its potential targets in GC, we performed transcriptome-sequencing to compare the gene expression profile following FTO depletion in AGS cells. We found that 4852 genes were significantly down-regulated, while 3134 genes were significantly up-regulated (Fig. 4A and Supplementary Table 1). Among these potential top up-regulated genes, we focused on caveolin-1 due to its dramatic elevation (Fig. 4A). The elevation of caveolin-1 mRNA in FTO-depleted AGS cells was verified by quantitative reverse-transcription PCR (qRT-PCR) (Fig. 4B). Moreover, over-expression of wild-type FTO, not mutant FTO (R316A) lacking demethylation activity, decreased the expression of caveolin-1 at the mRNA level (Fig. 4B). Additionally, we found a very high confidence m6Am modification site at the 200 bp of caveolin-1 CDS region using m6Am modification site predictor SRAMP (Fig. 4C). Similar changes were observed in the methylated caveolin-1 mRNA by Me-RIP-qPCR (Fig. 4D). The changes in protein levels were also confirmed by Western blotting analysis (Fig. 4E). Transcription inhibition assay further showed that FTO depletion dramatically attenuated the degradation rate of caveolin-1 mRNA (Fig. 4F). In contrast, over-expression of wild-type FTO, not mutant FTO (R316A) lacking demethylation activity, enhanced the degradation rate of caveolin-1 mRNA (Fig. 4F). These data collectively suggested that FTO directly targeted caveolin-1 mRNA and promoted its degradation.

![Fig. 2](image-url)  
**Fig. 2** Down-regulated m6A and elevated level of FTO are shown in GC liver metastasis tissues. A The level of m6A methylated RNA in the tumor and liver metastasis tumor was analyzed by Colorimetric kit. B The level of m6A methylated RNA in the tumor and liver metastasis tumor was confirmed by m6A Dot blotting analysis. C The expression of FTO at the mRNA level was analyzed by qRT-PCR. D The level of m6A was negatively relative with FTO mRNA expression in the tumor and liver metastasis tumor. E The expression of FTO at the protein level was analyzed by IF. N = 5, *p < 0.05, **p < 0.01 compared with the indicated group.

| Variables          | FTO expression level | p Value |
|--------------------|----------------------|---------|
| Variables          | Low | High |         |
| Age                |     |      |         |
| ≤60 years          | 4   | 36   | 0.135   |
| >60 years          | 13  | 37   |         |
| Gender             |     |      |         |
| Male               | 12  | 54   | 1.000   |
| Female             | 8   | 16   |         |
| T stage            |     |      |         |
| T1                 | 0   | 5    | 0.001   |
| T2                 | 3   | 7    |         |
| T3                 | 9   | 26   |         |
| T4                 | 8   | 32   |         |
| N stage            |     |      |         |
| N0                 | 14  | 17   | 0.001   |
| N1                 | 10  | 9    |         |
| N2                 | 2   | 15   |         |
| N3                 | 3   | 20   |         |
| M stage            |     |      |         |
| M0                 | 24  | 45   | 0.001   |
| M1                 | 6   | 15   |         |
| TNM stage          |     |      |         |
| I/II               | 11  | 20   | <0.001  |
| III/IV             | 19  | 40   |         |
| Liver metastasis   |     |      |         |
| Negative           | 32  | 33   | 0.008   |
| Positive           | 5   | 20   |         |

Italic font signifies p < 0.05.
FTO depletion impairs the proliferation, migration, and invasion of GC cells via inhibiting caveolin-1

To further understand the role of caveolin-1 in the FTO-regulated biological functions of GC cells, we then analyzed the expression of FTO in liver metastasis. The result showed a low-expression level of caveolin-1 in GC liver metastasis tissues from mouse models by qRT-PCR (Fig. 5A) and IHC (Fig. 5B). We then confirmed these findings using the GC tissue microarray consisting of 90 cases by IHC. Figure 5C reveals that caveolin-1 was clearly located in the cytoplasm of GC cells. Besides, the positive expression of caveolin-1 was dominant in most GC tissues with no liver metastasis, which was further confirmed by quantitative analysis (Fig. 5D). Among them, 58 cases (64.44%) had weak staining, and 32 cases (35.55%) had strong staining. Besides, the expression of caveolin-1 was significantly decreased with the increase of pN stage ($p = 0.004$), pT stage ($p < 0.001$), TNM stage ($p < 0.001$), and invasion ability ($p = 0.012$) (Table 2). Notably, we found that caveolin-1 depletion did not affect the cellular viability (Fig. 5E), but elevated the colony formation (Fig. 5F) and invasion ability (Fig. 5G) in AGS and SGC-7901 cells. Moreover, caveolin-1 depletion significantly attenuated the FTO depletion-inhibited cellular viability (Fig. 5E), colony formation (Fig. 5F), and invasion ability (Fig. 5G) in AGS and SGC-7901 cells. Taken together, these data suggested that FTO impaired the proliferation, migration, and invasion of GC cells via inhibiting caveolin-1.

FTO depletion impairs the mitochondrial metabolism of GC cells via caveolin-1

Mitochondria play an important role in the cellular biochemistry of most eukaryotic cells, which produce nearly 95% of cellular ATP through oxidative phosphorylation of mitochondria, thereby controlling cell death or survival. Considering the critical role of caveolin-1 in the regulation of mitochondrial metabolism, we then tested whether FTO promoted the biological functions of GC cells via caveolin-1-dependent regulation of mitochondrial metabolism. To test this hypothesis, we determined the effects of FTO and caveolin-1 on mitochondrial respiration (OXPHOS) using the Seahorse XF24 Extracellular Flux Analyzer. FTO depletion dramatically reduced the ATP content (Fig. 6A), ATP synthase activity (Fig. 6B), and cellular OCR (Fig. 6C), indicating reduced OXPHOS in AGS and SGC-7901 cells. Furthermore, we assessed specific mitochondrial functions, in particular basal respiration, maximal respiration, ATP production, spare respiratory capacity, proton leak, and non-mitochondrial respiration. FTO depletion dramatically reduced the OCR value of basal respiration, maximal respiration, ATP production, and spare respiratory capacity in AGS and SGC-7901 cells. In contrast, caveolin-1 depletion significantly attenuated the inhibitory effect of FTO on the ATP content, ATP synthase activity, and cellular OCR. These data...
indicated that FTO depletion suppressed mitochondrial respiration via elevating caveolin-1, which might result in reduced ATP supplement and thereby restrict cancer cell growth.

**FTO depletion induces mitochondrial fission in GC cells via caveolin-1**

When mitochondria are destroyed by stresses, such as reactive oxygen species, the balance of mitochondrial dynamics is destroyed, leading to mitochondrial fission. Here, we determined whether FTO depletion altered the mitochondrial dynamics of cancer cells. MitoTracker Green staining and confocal microscopy were used to observe the cell morphology. Compared with untreated control cells, the proportion of mitochondrial fragments in FTO-depleted GC cells was increased, while the proportion of elongated mitochondria was decreased (Fig. 7A). Caveolin-1 did not change the morphology of mitochondria, whereas it reversed the FTO depletion-increased fragmented mitochondria and decreased elongated mitochondria (Fig. 7A). Mitochondrial fission and fusion are regulated by mitochondrial motion-related GTPases, such as Pink1, Parkin1, and MFN2, which thus induce the mitochondrial pathway of apoptosis via cytochrome c release from mitochondria. Figure 7B shows that FTO depletion significantly decreased the expressions of Pink1, phosphorylated Parkin1 and phosphorylated MFN2 at the protein level in AGS cells, which was similarly reversed by caveolin-1 depletion. Moreover, FTO depletion enhanced the release of mitochondrial cytochrome c into the cytoplasm, which was also reversed by caveolin-1 depletion (Fig. 7C). Accordingly, mitochondrial fission inhibitor Mdivi-1 significantly suppressed the cell proliferation of FTO overexpressed AGS and SGC-7901 cells (Supplementary Fig. 1). The above-mentioned results showed that FTO depletion induced mitochondrial fission in GC cells via caveolin-1.

**FTO depletion impairs the tumor growth via caveolin-1 in the xenograft model**

To further confirm the effect of FTO/caveolin-1 signaling on tumor growth in vivo, a subcutaneous tumor xenograft in Balb/c nude mice was established. FTO depletion consistently inhibited the tumor growth (Fig. 8A, B) and decreased the tumor weight (Fig. 8C). Caveolin-1 depletion did not affect the tumor growth of
Fig. 5  FTO depletion impairs the proliferation, migration, and invasion of GC cells via inhibiting caveolin-1. A The expression of caveolin-1 at the mRNA level in the tumor and liver metastasis tumor was analyzed by qRT-PCR. B The expression of caveolin-1 at the protein level in the tumor and liver metastasis tumor was analyzed by IHC. C The expression of caveolin-1 at the protein level in the GC tissue microarray consisting of 90 cases was analyzed using IHC, and D quantitative analysis was performed using the IHC data. E The effect of caveolin-1 depletion on the cellular viability of AGS and SGC-7901 cells with or without FTO depletion was analyzed by CCK-8 assay. F The effect of caveolin-1 depletion on the proliferation of AGS and SGC-7901 cells with or without FTO depletion was analyzed by colony formation assay. G The effect of caveolin-1 depletion on the invasion of AGS and SGC-7901 cells with or without FTO depletion was analyzed by transwell assay. $N = 3$, *$p < 0.05$, **$p < 0.01$ compared with the indicated group.
AGS cells, whereas it completely reversed the FTO-inhibited tumor growth (Fig. 8A, B) and reduced the tumor weight (Fig. 8C). Furthermore, the expressions of FTO and caveolin-1 at the protein level in these generated tumors were confirmed by IHC (Fig. 8D). FTO depletion dramatically reduced the ATP content in the generated tumors, which was reversed by caveolin-1 depletion (Fig. 8E). Consistently, FTO depletion significantly decreased the expressions of Pink1, phosphorylated Parkin1 and phosphorylated MFN2 at the protein level in the generated tumors, which was similarly reversed by caveolin-1 depletion (Fig. 8F). To further confirm the effect of FTO/caveolin-1 signaling on tumor metastasis in vivo, a Tail Vein injection tumor metastasis xenograft in Balb/c nude mice was established. As shown in Fig. 8G, FTO depletion significantly decreased the number of lung metastasis lesion, which was reversed by caveolin-1 depletion. These results collectively suggested that FTO depletion impaired the tumor growth and metastasis via caveolin-1 in the xenograft model.

DISCUSSION
Methylation plays an important role in a variety of biological and pathological processes, including tumorigenesis [20, 22, 23]. Methylation is thought to regulate the unwinding and transcription of DNA, and with the increasing understanding of epigenetic control, the comprehension of nucleic acid methylation has been expanded from DNA to RNA. As the most common epigenetic modification on eukaryotic RNA, m^6^A is specified by methylation of adenosine and controlled by author, reader, and eraser [24, 25]. The degree of m^6^A modification is weakened by the writer enhancement or eraser, while the reader can recognize and play the role in m^6^A modification, although it does not directly affect the level of m^6^A [26]. RNA m^6^A modification has been reported to influence carcinogenesis [27–29], while its role in the regulation of GC carcinogenesis and progression remains largely undetermined.

### Table 2. Association between caveolin-1 expression and clinicopathological characteristics in gastric cancer.

| Variables          | Caveolin-1 expression level | p Value |
|--------------------|-----------------------------|---------|
|                    | Low | High |
| Age                |     |      |
| ≤60 years          | 23  | 17   | 0.135 |
| >60 years          | 26  | 24   |       |
| Gender             |     |      |
| Male               | 37  | 30   | 0.856 |
| Female             | 13  | 10   |       |
| T stage            |     |      |
| T1                 | 3   | 2    | <0.001|
| T2                 | 6   | 4    |       |
| T3                 | 31  | 8    |       |
| T4                 | 23  | 13   |       |
| N stage            |     |      |
| N0                 | 16  | 9    | 0.004 |
| N1                 | 15  | 2    |       |
| N2                 | 5   | 14   |       |
| N3                 | 16  | 13   |       |
| M stage            |     |      |
| M0                 | 35  | 34   | <0.001|
| M1                 | 11  | 10   |       |
| TNM stage          |     |      |
| I/II               | 26  | 9    | <0.001|
| III/IV             | 37  | 18   |       |
| Liver metastasis   |     |      |
| Negative           | 35  | 20   | 0.012 |
| Positive           | 25  | 10   |       |

Italic font signifies p < 0.05.

Fig. 6 FTO depletion impairs the mitochondrial metabolism of GC cells via caveolin-1. A The effect of caveolin-1 depletion on the ATP content of AGS and SGC-7901 cells with or without FTO depletion was analyzed. B The effect of caveolin-1 depletion on the ATP synthase activity of AGS and SGC-7901 cells with or without FTO depletion was analyzed. C The effects of FTO and caveolin-1 on mitochondrial respiration (OXPHOS) were tested using the Seahorse XF24 Extracellular Flux Analyzer. N = 3, *p < 0.05, **p < 0.01 compared with the indicated group.
Fig. 7  FTO depletion induces mitochondrial fission in GC cells via caveolin-1. A MTG staining and confocal microscopy were used to observe the mitochondrial fragmentation in AGS cells. B The regulatory molecules of mitochondrial fission and fusion, including Pink1, Parkin1, and MFN2, were analyzed. C The regulatory molecule of mitochondrial pathway apoptosis, indicated by cytochrome c release from mitochondria, was analyzed. N = 3, *p < 0.05, **p < 0.01 compared with the indicated group.
FTO was originally thought to be a regulator of body weight and obesity because FTO deficiency leads to growth retardation, while FTO overactivation increases food intake and contributes to obesity [30]. After FTO is identified as the first RNA demethylation enzyme that can remove m^6^A from RNA through an α-ketoglutarate, it has been found to have new functions to control different aspects of biological processes, such as dopaminergic signaling and fat formation [31]. More importantly, there is growing evidence that FTO dysfunction can promote the development of cancers, such as acute myeloid leukemia (AML) [32], melanoma [33], breast cancer [34], and lung cancer [35]. FTO is considered as a prognostic factor of lung squamous cell carcinoma, promoting cell proliferation and invasion, but inhibiting cell apoptosis by regulating the expression of MZF1 [35]. It has

![Fig. 8 FTO depletion impairs the tumor growth via caveolin-1 in a xenograft model. A To further confirm the effect of FTO/caveolin-1 signaling on tumor growth in vivo, a subcutaneous tumor xenograft in Balb/c nude mice was established. B The curve of tumor growth and C tumor weight was analyzed. D The expressions of FTO and caveolin-1 at the protein level in these generated tumors were confirmed by IHC. E The ATP content in these generated tumors was analyzed. F The regulatory molecules of mitochondrial fission and fusion, including Pink1, Parkin1, and MFN2 in these generated tumors, were analyzed. G To further confirm the effect of FTO/caveolin-1 signaling on tumor metastasis in vivo, a Tail Vein injection tumor xenograft in Balb/c nude mice was established. The lung metastasis lesions from four groups of AGS cells were analyzed. H A working model demonstrates that the key demethylase of m^6^A FTO promotes the proliferation and metastasis of gastric cancer via the degradation of caveolin-1 mRNA and regulating the mitochondrial fission/fusion and metabolism. N = 5, *p < 0.05, **p < 0.01 compared with the indicated group.](image)
been recently reported that FTO plays a critical oncopgenic role in hematopoietic cell transformation and AML as an m^6^A demethylase [32]. Moreover, FTO plays critical roles in self-renewal and immune evasion of cancer stem cells, and small-molecule FTO inhibitors can exhibit strong anti-tumor effects in multiple types of cancer [36]. In the present study, we identified that the depletion of a critical m^6^A eraser FTO promoted the proliferation and metastasis in GC cells.

Caveolin-1 is a complete membrane protein that is expressed in large amounts in adipocytes, endothelial cells, lung cells, fibroblasts, and muscle cells [37]. Caveolin-1 plays an important role in cancerogenesis because it is overexpressed or mutated in many solid human tumors [38–40]. However, the role of epithelial caveolin-1 in tumorogenesis remains controversial. Notably, caveolin-1 has been shown to act as an anti-apoptotic and pro-apoptotic protein, both as a tumor promoter and a tumor suppressor [41]. Besides, caveolin-1 can stimulate metastasis and serve as a prognostic marker [42]. Transcriptional analysis shows that many oncogenes down-regulate the expression of caveolin-1 [43]. Besides, the gene encoding caveolin-1 is located at a putative tumor suppressor gene locus. Finally, it has been hypothesized that caveolin-1 is a tumor suppressor [44]. However, loss of caveolin-1 expression has also been found to be associated with increased independent growth of the anchor, reflecting its metastatic potential. However, for some tumors, the up-regulation of caveolin-1 can affect the survival and growth of cancer cells and facilitate tumor progression. Herein, we found that caveolin-1 was critical for the FTO depletion-impaired cell proliferation and metastasis. FTO directly targeted the caveolin-1 mRNA and promoted its degradation.

In terms of mechanism, caveolin-1 is associated with the mitochondrial number and bioenergy function in various cell types [45]. For example, mitochondria of hypercholesterolemic rabbit hepatocytes are found to have a high caveolin-1 expression [46]. Compared with the control group, intravenous injection of antenna-caveolin-1 (AP-caveolin-1) peptide in mice increases the transmembrane transposition of caveolin-1, which results in a mitochondrial matrix with deeper electron density and a decrease in superoxide dismutase and catalase activities, suggesting that caveolin-1 is necessary for maintaining mitochondrial structure and function [41, 47, 48]. AP-caveolin-1 treatment also restores respiratory chain subunit protein (complex I-V), preserves mitochondrial function, and inhibits apoptotic cell death [49]. Colon cancer cells with over-expression of caveolin-1 (HCT116) also have abundant mitochondrial localization, and in low-expression cells (HT29), over-expression of caveolin-1 leads to its enrichment in mitochondria and reduced apoptosis [50]. These findings provide clues that caveolin-1 enhances mitochondrial function to support tumor progression, the details of which remain unclear. On the other hand, high expression of caveolin-1 in mitochondria inhibits the proliferation of H-Ras-driven tumor cells [51]. Specifically, tumor transformation triggered by tumorigenic H-RAS12V in NIH3T3 cells inhibits intracellular basal calcium (Ca^{2+}) levels, Ca^{2+} influx, and caveolin-1 expression [51, 52]. Besides, re-introduction of caveolin-1 can enhance mitochondrial Ca^{2+} uptake, inhibit cell growth and colony formation, and induce cell apoptosis, suggesting that a high caveolin-1 level inhibits mitochondrial function, thereby mediating the inhibitory activity of H-Ras-driven tumors [53]. In our present study, we found that FTO depletion markedly induced mitochondrial fission and inhibited mitochondrial metabolism. However, these effects were dominantly reversed by caveolin-1 inhibition, suggesting that the effect of FTO depletion on the mitochondria relied on the up-regulation of caveolin-1 mRNA.

In conclusion, this study demonstrated that the key demethylase of m^6^A FTO promotes the proliferation and metastasis of GC via regulating the mitochondrial fission/fusion and metabolism. In terms of mechanism, FTO improved the degradation of caveolin-1 mRNA via its demethylation (Fig. 8H). Collectively, our findings provided valuable insights into FTO-mediated m^6^A demethylation modification, which could be used as a new strategy for more careful surveillance and aggressive therapeutic intervention.

**DATA AVAILABILITY**

RNA-seq data supporting the results of this study has been deposited in the NCBI GEO database under accession number GSE178697.

**REFERENCES**

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. 2021. CA Cancer J Clin. 2021;71:3–33.
2. Zhang XY, Zhang PY. Gastric cancer: somatic genetics as a guide to therapy. J Med Genet. 2016;54:305–10.
3. Smyth EC, Nilsson M, Grabhsch HL, van Grieken NCT, Lordick F. Gastric cancer. Lancet. 2020;396:635–48.
4. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.
5. Porporato PE, Filigheddu N, Pedro JMB-S, Kroemer G, Galluzzi L. Mitochondrial metabolism and cancer. Cell Res. 2018;28:265–80.
6. Srinivasan S, Srinivasan S, Guha M, Guha M, Kashina A, Kashina A, et al. Mitochondrial dysfunction and mitochondrial dynamics—the cancer connection. Biochim Biophys Acta Bioenerg. 2017;1858:602–14.
7. Zacksenhaus E, Shrestha M, Liu JC, Vorobieva I, Chung PED, Ju Y, et al. Mitochondrial OXPHOS induced by R81 deficiency in breast cancer: implications for anabolic metabolism, stemness, and metastasis. Trends Cancer. 2017;3:768–79.
8. Bock FJ, Tait S. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2019;21:85–100.
9. Sergey P, Francesca C, Silvia B, Andrea F. Targeting mitochondria in cancer: current concepts and immunotherapy approaches. Trans Res. 2018;202:35–31.
10. Rossi A, Pizzo P, Filadri R. Calcium, mitochondria and cell metabolism: a functional triangle in bioenergetics. Biochim Biophys Acta Mol Cell Res. 2019;1866:1068–78.
11. Signorile A, Sgaramella G, Bellomo F, De Raso M. Prognostics: a critical role in mitochondrial functions and implication in diseases. Cells. 2019;8:71.
12. Heyn H, Esteller M. An adenosine code for DNA: a second life for N6-methyladenine. Cell. 2015;161:710–3.
13. Yoon KJ, Ringelng FR, Vissers C, Jacob F, Pokrass M, Jimenez-Cyurus D, et al. Temporal Control of Mammalian cortical neurogenesis by m6A methylation. Cell. 2017;171:877–89 e17.
14. Wang J, Wang J, Gu Q, Ma Y, Yang Y, Zhu J, et al. The biological function of m6A demethylase ALKBH5 and its role in human disease. Cancer Cell Int. 2020;20:347.
15. Xiang Y, Laurent B, HSU CH, Nachtergaele S, Lu Z, Sheng W, et al. RNA m6A methyltransfer regulates the ultraviolet-induced DNA damage response. Nature. 2017;552:573–6.
16. Chen M, Wei L, Law CT, Tsang HC, Shen J, Cheng LH, et al. RNA N6-methyladenosine methyltransferase METTL3 promotes liver cancer progression through YTHFD2 dependent post-transcriptional silencing of SCOC25. Hepatology. 2017;66:2254–70.
17. Cui Q, Shi H, Ye P, Li L, Qu Q, Sun G, et al. m6A RNA methylation regulates the self-renewal and tumorogenesis of glioblastoma stem cells. Cell Rep. 2017;20:2622–34.
18. Gu C, Shi X, Dai C, Shen F, Rocco G, Chen J, et al. RNA m6A modification in cancers: molecular mechanisms and potential clinical applications. Innovation. 2020;2:100066.
19. He L, Li H, Wu A, Peng Y, Yin G. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;18:176.
20. Zhang Y, Xing X, Li Q, Xu J, Wang H. m6A modification in RNA: biogenesis, functions and roles in gliomas. J Exp Clin Cancer Res. 2020;39:192.
21. Zhao W, Qi X, Liu L, Liu Z, Ma S, Wu J. Epigenetic regulation of m6A modifications in human cancer. Mol Ther Nucleic Acids. 2019;19:405–12.
22. Erson-Bensan AE, Begik O. m6A modification and implications for microRNAs. Microrna. 2017;6:97–10.
23. Meyer KD, Jaffrey SR. Rethinking m6A readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319–42.
24. Ma S, Chen C, Xi J, Liu J, Sun Z. The interplay between m6A RNA methylation and noncoding RNA in cancer. J Hematol Oncol. 2019;12:121.
25. Zaccara S, Ries RJ, Jaffrey SR. Reading, writing and erasing mRNA methylation. Nat Rev Mol Cell Biol. 2019;20:608–24.
26. Meyer KD, Jaffrey SR. Rethinking m6A readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319–42.
27. Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed Pharmacother. 2019;112:108613.
28. Vu LP, Cheng Y, Kharas MG. The biology of m 6 A RNA methylation in normal and malignant hematopoiesis. Cancer Discov. 2018;9:25–33.
29. Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19:88.
30. Zhao X, Yang Y, Sun BF, Zhao YL, Yang YG. FTO and obesity: mechanisms of association. Curr Diab Rep. 2014;14:486.
31. Marek B, Covelo MH, Pavlina G, Dominika H, Grzegorz K, Stepanka V. N6-methyladenosine demethylase FTO targets pre-mRNAs and regulates alternative splicing and 3′-end processing. Nucleic Acids Res. 2017;45:11356–70.
32. Huang Y, Su R, Sheng Y, Dong L, Dong Z, Xu H, et al. Small-molecule targeting of oncogenic FTO demethylase in acute myeloid leukemia. Cancer Cell. 2019;35:677–91. e10
33. Yang S, Wei J, Cui YH, Park G, Shah P, Deng Y, et al. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. Nat Commun. 2019;10:2782.
34. Niu Y, Lin Z, Wan A, Chen H, Liang H, Sun L, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18:46.
35. Liu J, Ren D, Du Z, Wang H, Hua Z, Jin Y. m 6 A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating M2F1 expression. Biochem Biophys Res Commun. 2018;502:456–64.
36. Wu YJ, Huang TW, Hsieh VT, Wang YF, Yen CC, Lee GL, et al. Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell. 2020;77:213–27.
37. Boscher C, Nabi IR. CAVEOLIN-1: role in cell signaling. Adv Exp Med Biol. 2012;729:29–50.
38. Fernandez-Rojo MA, Ramm GA. Caveolin-1 function in liver physiology and disease. Trends Mol Med. 2016;22:889–904.
39. Ketteler J, Klein D. Caveolin-1 and cancer therapy resistance. Int J Cancer. 2018;143:2092–104.
40. Núñez-Wehinger S, Ortiz RJ, Díaz N, Díaz J, Quest A. Caveolin-1 in cell migration and metastasis. Curr Mol Med. 2014;14:255–74.
41. Nwosu ZC, Ebert MP, Dooley S, Meyer C. Caveolin-1 in the regulation of cell metabolism: a cancer perspective. Mol Cancer. 2016;15:71.
42. Parat MO, Riggins GJ. Caveolin-1, caveolae, and glioblastoma. Neuro Oncol. 2012;14:679–88.
43. Volonte D, Galbiati F. Caveolin-1, a master regulator of cellular senescence. Cancer Metastasis Rev. 2020;39:397–414.
44. Huang H, Zhang J, Wu Q, Chen X, Zhang J. Caveolin-1 promotes invasion and metastasis by upregulating Pofut1 expression in mouse hepatocellular carcinoma. Cell Death Dis. 2019;10:477.
45. Asterholm IW, Mundy D, Jian W, Anderson RW, Scherer P. Altered mitochondrial function and metabolic inflexibility associated with loss of caveolin-1. Cell Metab. 2012;15:171–85.
46. Fridolfsson HN, Roth DM, Insel PA, Patel HH. Regulation of intracellular signaling and function by caveolin. Farad J. 2011:3823–31.
47. Mastrodonato M, Portincasa P, Mentino D, Rossi R, Resta L, Ferri D, et al. Caveolin-1 and mitochondrial alterations in regenerating rat liver. Microsc Res Tech. 2012;75:1026–32.
48. Shiratori T, Romero N, Sugiyama T, Sartoretto JL, Kalwa H, Yan Z, et al. Caveolin-1 is a critical determinant of autophagy, metabolic switching, and oxidative stress in vascular endothelium. PLoS ONE. 2014;9:e87871.
49. Volonte D, Liu Z, Shiva S, Galbiati F. Caveolin-1 controls mitochondrial function through regulation of m-AAA mitochondrial protease. Aging. 2016;8:2355–69.
50. Yu DM, Jung SH, An HT, Lee S, Hong J, Park JS, et al. Caveolin-1 deficiency induces premature senescence and mitochondrial dysfunction. Aging Cell. 2017;16:773–84.
51. Kortum RL, Fernandez MR, Costanzo-Garvey DL, Johnson HJ, Fisher KW, Volle DJ, et al. Caveolin-1 is required for kinase suppressor of Ras 1 (KSR1)-mediated extracellular signal-regulated kinase 1/2 activation, H-RasV12-induced senescence, and transformation. Mol Cell Biol. 2014;34:3461–72.
52. Kwiattek AM, Minshall RD, Cool DR, Skidgel RA, Malik AB, Tiruppathi C. Caveolin-1 regulates store-operated Ca2+- influx by binding of its scaffolding domain to transient receptor potential channel-1 in endothelial cells. Mol Pharm. 2006;70:1174–83.
53. Suzuki Y, Yamamura H, Ohya S, Imaizumi Y. Caveolin-1 facilitates the direct coupling between large conductance Ca2+-activated K+ (BKCa) and Cav1.2 Ca2+ channels and their clustering to regulate membrane excitability in vascular myocytes. J Biol Chem. 2013;288:36750–61.

AUTHOR CONTRIBUTIONS
YZ, YS, and JJ conceived the study, QW, XZ, BX, and HD performed the experiments. JL and YL analyzed and interpreted the data. All authors contributed to biological analysis, interpretation of the results, read, and approved the final version of the manuscript.

FUNDING
This project was supported by grants from the National Key R&D Plan (2018YFC1313400), National Natural Science Foundation of China (31701111, 81902386), National Science Foundation of Jiangsu Province (BK20211065), Young Talent Development Plan of Changzhou Health Commission (CZQM2020008, CZQM2020018), Youth Talent Science and Technology Project of Changzhou Health Commission (QN202014), and Applied Basic Research Foundation of Changzhou (CJ20190094).

COMPETING INTERESTS
The authors declare no competing interests.

INFORMED CONSENT
All authors agreed on the manuscript.

ADDITIONAL INFORMATION
Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-022-04503-7.

Correspondence and requests for materials should be addressed to Xiao Zheng or Jingting Jiang.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022